MktsMarkets

Anavex Life Sciences Corp.
NASDAQ: AVXLKey statistics
AVXL News
Stories mentioning AVXL from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 | Q1 '24Mar 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 4,656 | 7,295 | 9,959 | 9,892 | 10,446 | 11,614 | 11,811 | 9,729 |
| Sales General & Admin | 2,126 | 3,146 | ||||||
| Total Operating Expenses | 6,782 | 10,844 | 14,459 | 12,513 | 13,592 | 14,272 | 14,603 | 12,624 |
| Operating Income (Loss) | (6,782) | (10,844) | (14,459) | (12,513) | (13,592) | (14,272) | (14,603) | (12,624) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (11,743) | (12,281) | (10,441) | |||||
| Tax Provision | 18.00 | |||||||
| Net Income (Loss) | (5,681) | (9,827) | (13,243) | (11,196) | (12,111) | (11,620) | (12,214) | (10,546) |
| Earnings Per Share (Basic) | (0.06) | (0.12) | (0.16) | (0.13) | (0.14) | (0.14) | (0.14) | (0.13) |
| Earnings Per Share (Diluted) | (0.06) | (0.12) | (0.16) | (0.13) | (0.14) | (0.14) | (0.14) | (0.13) |
| Weighted Average Shares Outstanding (Basic) | 89,029 | 85,289 | 85,381 | 85,074 | 84,806 | 83,468 | 84,535 | 82,464 |
| Weighted Average Shares Outstanding (Diluted) | 89,029 | 85,289 | 85,381 | 85,074 | 84,806 | 83,468 | 84,535 | 82,464 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About AVXL
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a stock listed on the Nasdaq Stock Market under the ticker symbol AVXL. It last traded at $0.6300 (Nov 20, 2026, 2:15 PM ET), down 6.2% on the day. That gives Anavex Life Sciences a market capitalisation of $62.0M.
Over the past 52 weeks AVXL has traded between $0.7100 and $5.36.
For the quarter ended Dec 31, 2025 it reported a net loss of $5.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Dec 31, 2025 | — | -$5.7M |
| Sep 30, 2025 | — | -$9.8M |
| Jun 30, 2025 | — | -$13.2M |
| Mar 31, 2025 | — | -$11.2M |
From Anavex Life Sciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…